Walleye Capital LLC bought a new position in shares of Savara Inc. (NASDAQ:SVRA - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 207,299 shares of the company's stock, valued at approximately $574,000. Walleye Capital LLC owned about 0.12% of Savara at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Savara by 24.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 156,983 shares of the company's stock valued at $482,000 after purchasing an additional 31,168 shares during the last quarter. Millennium Management LLC grew its position in Savara by 71.8% in the 4th quarter. Millennium Management LLC now owns 482,263 shares of the company's stock valued at $1,481,000 after buying an additional 201,599 shares during the last quarter. Deutsche Bank AG grew its position in Savara by 6.1% in the 4th quarter. Deutsche Bank AG now owns 927,595 shares of the company's stock valued at $2,848,000 after buying an additional 53,054 shares during the last quarter. D. E. Shaw & Co. Inc. boosted its holdings in shares of Savara by 314.7% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 70,560 shares of the company's stock valued at $217,000 after acquiring an additional 53,547 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its holdings in shares of Savara by 25.3% in the first quarter. Farther Finance Advisors LLC now owns 32,314 shares of the company's stock valued at $92,000 after acquiring an additional 6,532 shares in the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.
Insider Activity at Savara
In other Savara news, Director Richard J. Hawkins purchased 48,225 shares of the business's stock in a transaction that occurred on Friday, June 20th. The shares were purchased at an average price of $2.04 per share, for a total transaction of $98,379.00. Following the completion of the acquisition, the director owned 115,466 shares of the company's stock, valued at approximately $235,550.64. This represents a 71.72% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.33% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
A number of brokerages have weighed in on SVRA. Guggenheim reaffirmed a "buy" rating and issued a $8.00 price objective (down previously from $9.00) on shares of Savara in a report on Wednesday, May 28th. Oppenheimer lifted their price target on Savara from $5.00 to $6.00 and gave the company an "outperform" rating in a research note on Friday, August 15th. Wells Fargo & Company decreased their target price on shares of Savara from $8.00 to $7.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 28th. HC Wainwright boosted their target price on shares of Savara from $5.00 to $8.00 and gave the stock a "buy" rating in a research report on Wednesday. Finally, Evercore ISI decreased their price objective on shares of Savara from $3.00 to $2.00 and set an "in-line" rating on the stock in a report on Wednesday, May 28th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Savara presently has a consensus rating of "Moderate Buy" and a consensus target price of $6.67.
Read Our Latest Report on SVRA
Savara Price Performance
Shares of NASDAQ:SVRA traded up $0.16 on Thursday, hitting $3.58. The company had a trading volume of 1,775,465 shares, compared to its average volume of 1,278,540. Savara Inc. has a 52-week low of $1.89 and a 52-week high of $4.70. The company has a market cap of $618.76 million, a PE ratio of -7.16 and a beta of 0.56. The business has a 50 day moving average of $2.66 and a 200 day moving average of $2.70. The company has a current ratio of 11.08, a quick ratio of 11.08 and a debt-to-equity ratio of 0.25.
Savara (NASDAQ:SVRA - Get Free Report) last released its earnings results on Wednesday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). As a group, equities analysts anticipate that Savara Inc. will post -0.45 earnings per share for the current fiscal year.
About Savara
(
Free Report)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Further Reading
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
